| Multiple Sclerosis, Secondary Progressive
Aubagio vs Tecfidera
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Aubagio vs Tecfidera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecfidera has a higher rate of injection site reactions vs Aubagio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecfidera but not Aubagio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aubagio
Tecfidera
At A Glance
Oral
Daily
Pyrimidine synthesis inhibitor
Oral
Twice daily
Nrf2 pathway activator
Indications
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 7 mg or 14 mg orally once daily; may be taken with or without food.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Starting dose 120 mg twice a day orally for 7 days; maintenance dose 240 mg twice a day orally.
Contraindications
- Severe hepatic impairment
- Pregnancy or females of reproductive potential not using effective contraception
- History of hypersensitivity reaction to teriflunomide, leflunomide, or any inactive ingredient (including anaphylaxis, angioedema, or serious skin reactions)
- Coadministration with leflunomide
- Known hypersensitivity to dimethyl fumarate or any excipient of TECFIDERA
Adverse Reactions
Most common (>=2% above placebo) Headache, increased alanine aminotransferase, diarrhea, alopecia, nausea, paresthesia, arthralgia, neutropenia, hypertension
Serious Hepatotoxicity, bone marrow effects/immunosuppression/infections, hypersensitivity reactions, serious skin reactions, DRESS, cutaneous or mucocutaneous ulcers and impaired wound healing, peripheral neuropathy, increased blood pressure, respiratory effects, pancreatitis (pediatric patients)
Postmarketing Thrombocytopenia, pancreatitis, colitis, drug-induced liver injury, anaphylaxis, angioedema, interstitial lung disease, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS, psoriasis (including pustular and nail), nail disorders, cutaneous or mucocutaneous ulcers, impaired wound healing
Most common (>=10%) Flushing, abdominal pain, diarrhea, nausea
Serious Anaphylaxis, angioedema, progressive multifocal leukoencephalopathy, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury
Postmarketing Acute pancreatitis, gastrointestinal perforation, ulceration, obstruction, and hemorrhage, liver function abnormalities, herpes zoster infection, rhinorrhea, alopecia
Pharmacology
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme required for de novo pyrimidine synthesis, which may reduce the number of activated lymphocytes in the CNS.
Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway involved in the cellular response to oxidative stress; the mechanism by which DMF exerts its therapeutic effect in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aubagio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (4/12)
Tecfidera
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Aubagio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Tecfidera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Aubagio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tecfidera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AubagioView full Aubagio profile
TecfideraView full Tecfidera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.